{"id":"palmidrol","rwe":[{"pmid":"41664677","year":"2026","title":"Efficacy, safety, and tolerability of palmitoylethanolamide in the management of diabetic neuropathic pain: a systematic review and meta-analysis.","finding":"","journal":"Journal of diabetes and metabolic disorders","studyType":"Clinical Study"},{"pmid":"36986081","year":"2023","title":"Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials.","finding":"","journal":"Nutrients","studyType":"Clinical Study"},{"pmid":"30621775","year":"2019","title":"Clinical applications of palmitoylethanolamide in pain management: protocol for a scoping review.","finding":"","journal":"Systematic reviews","studyType":"Clinical Study"},{"pmid":"28727699","year":"2017","title":"Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis.","finding":"","journal":"Pain physician","studyType":"Clinical Study"},{"pmid":"26604814","year":"2015","title":"Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome.","finding":"","journal":"Journal of pain research","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"G-protein coupled receptor 55","category":"target"},{"label":"GPR55","category":"gene"},{"label":"CNR1","category":"gene"},{"label":"CNR2","category":"gene"},{"label":"Active","category":"status"},{"label":"Analgesics","category":"pharmacology"},{"label":"Analgesics, Non-Narcotic","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents, Non-Steroidal","category":"pharmacology"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Antiviral Agents","category":"pharmacology"},{"label":"Cannabinoid Receptor Agonists","category":"pharmacology"},{"label":"Cannabinoid Receptor Modulators","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Hormones","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"phase_3","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"palmitoylethanolamide","offLabel":[],"synonyms":["palmidrol","palmitic acid monoethanolamide","palmitoylethanolamide","palmitic monoethanolamide"],"timeline":[],"approvals":[],"brandName":"Palmitoylethanolamide","ecosystem":[],"mechanism":{"target":"Cannabinoid receptor 2, Cannabinoid receptor 1, G-protein coupled receptor 55","targets":[{"gene":"GPR55","source":"DrugCentral","target":"G-protein coupled receptor 55","protein":"G-protein coupled receptor 55"},{"gene":"CNR1","source":"DrugCentral","target":"Cannabinoid receptor 1","protein":"Cannabinoid receptor 1"},{"gene":"CNR2","source":"DrugCentral","target":"Cannabinoid receptor 2","protein":"Cannabinoid receptor 2"}],"modality":"Small Molecule","explanation":"Imagine your body's pain and inflammation response like a fire alarm. When the alarm is triggered, it sends a signal to the brain, which can lead to pain and discomfort. Palmitoylethanolamide helps to turn off the fire alarm by binding to a specific receptor, reducing the signal sent to the brain and alleviating pain and inflammation.","oneSentence":"Palmitoylethanolamide works by binding to the G-protein coupled receptor 55, which helps regulate inflammation and pain.","technicalDetail":"Palmitoylethanolamide exerts its effects by interacting with the G-protein coupled receptor 55, a member of the GPCR family, which plays a crucial role in modulating inflammatory and pain responses through the activation of downstream signaling pathways."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2045","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=PALMIDROL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PALMIDROL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:12:49.282363","biosimilars":[],"competitors":[{"drugName":"cannabidiol","drugSlug":"cannabidiol","fdaApproval":"2018-06-25","patentExpiry":"Oct 13, 2035","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"cefapirin","drugSlug":"cefapirin","fdaApproval":"1974-03-12","relationship":"same-target"},{"drugName":"dronabinol","drugSlug":"dronabinol","fdaApproval":"1985-05-31","patentExpiry":"Aug 6, 2028","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"econazole","drugSlug":"econazole","fdaApproval":"1982-12-23","patentExpiry":"Aug 8, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"mestranol","drugSlug":"mestranol","fdaApproval":"1961-03-09","relationship":"same-target"},{"drugName":"mezlocillin","drugSlug":"mezlocillin","fdaApproval":"1981-09-21","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"miconazole","drugSlug":"miconazole","fdaApproval":"1974-01-08","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"nabilone","drugSlug":"nabilone","fdaApproval":"1985-12-26","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"nimodipine","drugSlug":"nimodipine","fdaApproval":"1988-12-28","patentExpiry":"Apr 16, 2038","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"orlistat","drugSlug":"orlistat","fdaApproval":"1999-04-23","patentStatus":"Unknown","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"palmidrol","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"cannabidiol","brandName":"cannabidiol","genericName":"cannabidiol","approvalYear":"2018","relationship":"same-target"},{"drugId":"cefapirin","brandName":"cefapirin","genericName":"cefapirin","approvalYear":"1974","relationship":"same-target"},{"drugId":"dronabinol","brandName":"dronabinol","genericName":"dronabinol","approvalYear":"1985","relationship":"same-target"},{"drugId":"econazole","brandName":"econazole","genericName":"econazole","approvalYear":"1982","relationship":"same-target"},{"drugId":"mestranol","brandName":"mestranol","genericName":"mestranol","approvalYear":"1961","relationship":"same-target"},{"drugId":"mezlocillin","brandName":"mezlocillin","genericName":"mezlocillin","approvalYear":"1981","relationship":"same-target"},{"drugId":"miconazole","brandName":"miconazole","genericName":"miconazole","approvalYear":"1974","relationship":"same-target"},{"drugId":"nabilone","brandName":"nabilone","genericName":"nabilone","approvalYear":"1985","relationship":"same-target"},{"drugId":"nimodipine","brandName":"nimodipine","genericName":"nimodipine","approvalYear":"1988","relationship":"same-target"},{"drugId":"orlistat","brandName":"orlistat","genericName":"orlistat","approvalYear":"1999","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT07377409","phase":"NA","title":"Beneficial Effects of Supplementation With CRONILIEF™ (Palmitoylethanolamide Phospholipids) in Diabetic Subjects With Neuropathic Pain.","status":"NOT_YET_RECRUITING","sponsor":"Azienda di Servizi alla Persona di Pavia","startDate":"2026-09-15","conditions":["Neuropathic Pain Management","Diabetic Neuropathies, Painful","Palmitoylethanolamide"],"enrollment":70,"completionDate":"2027-01-15"},{"nctId":"NCT07359534","phase":"NA","title":"Training Health Recovery and Improvement Via Levagen+® Evaluation","status":"RECRUITING","sponsor":"University of Westminster","startDate":"2025-03-10","conditions":["Exercise Recovery"],"enrollment":20,"completionDate":"2026-04-30"},{"nctId":"NCT07352514","phase":"","title":"Use of PEA and Scutellaria in Synergy With Therapeutic Exercise in Chemotherapy-induced Peripheral Neuropathy (CIPN): a Clinical Trial","status":"RECRUITING","sponsor":"University of Palermo","startDate":"2025-03-15","conditions":["Chemotherapy-induced Peripheral Neuropathy (CIPN)","Neuropathic Pain"],"enrollment":40,"completionDate":"2026-04"},{"nctId":"NCT07330765","phase":"PHASE1,PHASE2","title":"Analgesic Efficacy of Pre-Operative Dose of Palmitoylethanolamide in Patients Undergoing Total Knee Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"Abdelrahman Gaber Sayed Elkhateeb","startDate":"2026-01-13","conditions":["Total Knee Replacement"],"enrollment":1,"completionDate":"2027-10-13"},{"nctId":"NCT07316660","phase":"NA","title":"Palmitoylethanolamide vs Ibuprofen for Pain After ESWL","status":"NOT_YET_RECRUITING","sponsor":"Benha University","startDate":"2026-01-01","conditions":["Pain After Extracorporeal Shock Wave Lithotripsy","Palmitoylethanolamide"],"enrollment":120,"completionDate":"2026-07-01"},{"nctId":"NCT07315516","phase":"PHASE2","title":"Sleep and Stress Study","status":"NOT_YET_RECRUITING","sponsor":"RDC Clinical Pty Ltd","startDate":"2026-02","conditions":["Sleep Disorder (Disorder)","Stress","Anxiety"],"enrollment":240,"completionDate":"2027-02"},{"nctId":"NCT07305519","phase":"NA","title":"The Combined Effect of Magnesium, Palmitoylethanolamide, High-Molecular-weight Hyaluronic Acid, Vitamin B6, and Vitamin D in Preventing Preterm Birth:","status":"NOT_YET_RECRUITING","sponsor":"University of Roma La Sapienza","startDate":"2026-01-01","conditions":["Preterm Labor"],"enrollment":150,"completionDate":"2028-01-01"},{"nctId":"NCT07022938","phase":"PHASE4","title":"Nutritional Supplement for Treating Chemotherapy Induced Neuropathy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2021-11-01","conditions":["Cancer","Neuropathy","Chemotherapy Induced Pain Neuropathy","Chemotherapy-Induced Peripheral Neuropathy"],"enrollment":71,"completionDate":"2025-12-15"},{"nctId":"NCT06717867","phase":"PHASE2","title":"Long-Term PEA Safety Study","status":"RECRUITING","sponsor":"RDC Clinical Pty Ltd","startDate":"2025-01-22","conditions":["Healthy","Safety"],"enrollment":200,"completionDate":"2027-06"},{"nctId":"NCT06741358","phase":"PHASE4","title":"Using Glialia for Treating Persistent Perceptual Postural Dizziness","status":"RECRUITING","sponsor":"I.R.C.C.S. Fondazione Santa Lucia","startDate":"2024-12-21","conditions":["Persistent Postural Perceptual Dizziness"],"enrollment":30,"completionDate":"2026-10-10"},{"nctId":"NCT06694337","phase":"NA","title":"Study to Investigate the Potential Pharmacological Effect of Oral Palmitoylethanolamide (PEA) Therapy in the Management of Low Back Pain (Neuropathic Pain)","status":"COMPLETED","sponsor":"Liaquat University of Medical & Health Sciences","startDate":"2025-01-28","conditions":["Low Back Pain"],"enrollment":120,"completionDate":"2025-06-23"},{"nctId":"NCT05480072","phase":"EARLY_PHASE1","title":"Endocannabinoids, Stress, Craving And Pain Effects Study","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-01","conditions":["Opioid Use Disorder"],"enrollment":12,"completionDate":"2025-01-14"},{"nctId":"NCT06229977","phase":"PHASE2","title":"A Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2023-05-17","conditions":["Bipolar Depression"],"enrollment":34,"completionDate":"2025-07-17"},{"nctId":"NCT05246670","phase":"PHASE2","title":"PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2022-05-16","conditions":["Chemotherapy-Induced Peripheral Neuropathy","Hematopoietic and Lymphoid Cell Neoplasm","Malignant Solid Neoplasm"],"enrollment":88,"completionDate":"2026-02-28"},{"nctId":"NCT07110480","phase":"PHASE1,PHASE2","title":"Combination of Equisetum Arvense and Palmitoylethanolamide (PEA) for the Management of Patients With Chronic Pain in a Before-after Study","status":"COMPLETED","sponsor":"noiVita Srls","startDate":"2024-07-29","conditions":["Chronic Pain","Chronic Pain (Back / Neck)","Pain (Visceral, Somatic, or Neuropathic)","Pain Management"],"enrollment":50,"completionDate":"2025-04-30"},{"nctId":"NCT07013890","phase":"PHASE4","title":"Efficacy of Phycocyanin and Palmitoylethanolamide for the Treatment of Chronic Prostatitis Symptoms","status":"COMPLETED","sponsor":"Clinica Urologica Molinette - Città della Saliute e della Scienza","startDate":"2022-11-02","conditions":["Chronic Prostatitis (CP)","Chronic Prostatitis With Chronic Pelvic Pain Syndrome","Chronic Prostatitis/ Pelvic Pain Syndrome"],"enrollment":48,"completionDate":"2023-09-30"},{"nctId":"NCT07028528","phase":"PHASE2","title":"Levagen+ Efficacy Study on Diabetic Peripheral Neuropathy","status":"RECRUITING","sponsor":"RDC Clinical Pty Ltd","startDate":"2025-07-01","conditions":["Diabetic Peripheral Neuropathy"],"enrollment":80,"completionDate":"2026-05"},{"nctId":"NCT06432569","phase":"NA","title":"Evaluation of Butyrate and Palmitoylethanolamide in IBS Patients (B/P3_1)","status":"COMPLETED","sponsor":"University of Padova","startDate":"2024-03-08","conditions":["Irritable Bowel Syndrome With Diarrhea"],"enrollment":50,"completionDate":"2025-07-07"},{"nctId":"NCT07041060","phase":"NA","title":"Evaluation of the Efficacy and Safety of Eolo in Patients With NERD","status":"COMPLETED","sponsor":"University of Bologna","startDate":"2025-05-30","conditions":["Non-erosive Reflux Disease","Reflux Disease, Gastro-Esophageal","Nutraceutical"],"enrollment":60,"completionDate":"2025-05-30"},{"nctId":"NCT05182697","phase":"NA","title":"SCI-210 in the Treatment of Children and Young Adults With AutismEvaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD)","status":"RECRUITING","sponsor":"Neurothera Labs Inc.","startDate":"2024-02-21","conditions":["Autism Spectrum Disorder (ASD)"],"enrollment":60,"completionDate":"2026-06"},{"nctId":"NCT05126888","phase":"PHASE2","title":"SCI-110 in the Treatment of Tourette Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Neurothera Labs Inc.","startDate":"2025-08","conditions":["Tourette Syndrome"],"enrollment":164,"completionDate":"2026-02"},{"nctId":"NCT06790407","phase":"","title":"Observational Metabolic Health Study","status":"COMPLETED","sponsor":"Mimio Health, Inc.","startDate":"2024-08-26","conditions":["Healthy"],"enrollment":96,"completionDate":"2025-01-31"},{"nctId":"NCT06777680","phase":"NA","title":"Palmitoylethanolamide and Luteolin in Patients with Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Ospedali Riuniti Trieste","startDate":"2025-01","conditions":["Acute Ischemic Stroke AIS"],"enrollment":60,"completionDate":"2026-12"},{"nctId":"NCT05810116","phase":"PHASE4","title":"Effectiveness of PEA Compared to Placebo on Acute Menstrual Pain","status":"COMPLETED","sponsor":"RDC Clinical Pty Ltd","startDate":"2023-05-19","conditions":["Menstrual Pain"],"enrollment":80,"completionDate":"2023-12-20"},{"nctId":"NCT04489017","phase":"PHASE2","title":"Palmitoylethanolamide Combined With Luteoline in Frontotemporal Dementia Patients. A Randomized Controlled Trial","status":"COMPLETED","sponsor":"I.R.C.C.S. Fondazione Santa Lucia","startDate":"2019-06-01","conditions":["Frontotemporal Dementia"],"enrollment":50,"completionDate":"2023-06-30"},{"nctId":"NCT05406726","phase":"NA","title":"Mechanisms of Palmitoylethanolamide (PEA) to Alter Pain Sensitivity in Knee Osteoarthritis","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2023-03-22","conditions":["Osteoarthritis, Knee"],"enrollment":13,"completionDate":"2024-01-02"},{"nctId":"NCT06562400","phase":"","title":"Searching for Novel Therapeutic Approaches in Migraine Patients Resistant to Treatments","status":"RECRUITING","sponsor":"IRCCS National Neurological Institute \"C. Mondino\" Foundation","startDate":"2023-05-10","conditions":["Migraine Disorders","Chronic Migraine","Episodic Migraine"],"enrollment":45,"completionDate":"2026-05"},{"nctId":"NCT06273462","phase":"PHASE2","title":"Palmitoylethanolamide for Chronic Inflammatory Pain Conditions","status":"RECRUITING","sponsor":"Navy Medical Center San Diego","startDate":"2024-08-05","conditions":["Chronic Pain"],"enrollment":80,"completionDate":"2025-10-30"},{"nctId":"NCT05877781","phase":"NA","title":"PEA in Functional Dyspepsia","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2021-11-29","conditions":["Dyspepsia and Other Specified Disorders of Function of Stomach"],"enrollment":100,"completionDate":"2025-03-01"},{"nctId":"NCT06225440","phase":"NA","title":"Impact of Levagen+® Palmitoylethanolamide (PEA) in a Cross-Over Trial Examining Stress and Cognition in University Students","status":"COMPLETED","sponsor":"University of Westminster","startDate":"2022-09-01","conditions":["Wellness, Psychological","Well-Being, Psychological"],"enrollment":64,"completionDate":"2024-01-31"},{"nctId":"NCT05753111","phase":"NA","title":"Effect of PEA on Muscle Recovery Following Resistance Exercise","status":"COMPLETED","sponsor":"KU Leuven","startDate":"2023-02-16","conditions":["Muscle Recovery","Muscle Soreness"],"enrollment":11,"completionDate":"2023-05-26"},{"nctId":"NCT06187090","phase":"NA","title":"The Supplementation Therapy in Autism and Response to Treatment Study","status":"RECRUITING","sponsor":"University of Udine","startDate":"2023-09-01","conditions":["Autism","Autism Spectrum Disorder","Autism Spectrum Disorder High-Functioning","Asperger Syndrome","Depressive Symptoms","Anxiety State"],"enrollment":20,"completionDate":"2026-11"},{"nctId":"NCT06181175","phase":"NA","title":"Treatment of BPH With CO2 Serenoa +PEA as Monotherapy or in Combination With Tamsulosin: ProSeRePEA Trial","status":"UNKNOWN","sponsor":"Azienda Ospedaliero Universitaria Maggiore della Carita","startDate":"2021-10-01","conditions":["Benign Prostatic Hyperplasia","Urinary Obstruction","Lower Urinary Tract Symptoms"],"enrollment":250,"completionDate":"2025-04-30"},{"nctId":"NCT05003453","phase":"PHASE2,PHASE3","title":"The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema","status":"COMPLETED","sponsor":"RDC Clinical Pty Ltd","startDate":"2021-11-29","conditions":["Eczema, Atopic"],"enrollment":72,"completionDate":"2022-06-30"},{"nctId":"NCT04662827","phase":"NA","title":"The Effect of Palmitylethanolamide on Central and Peripheral Sensitization After Heat-induced Hyperalgesia","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2020-02-09","conditions":["Pain, Chronic","Pain, Acute","Central Sensitisation","Neuroinflammatory Response"],"enrollment":14,"completionDate":"2020-09-16"},{"nctId":"NCT05046522","phase":"PHASE3","title":"A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Migraines.","status":"COMPLETED","sponsor":"RDC Clinical Pty Ltd","startDate":"2021-09-01","conditions":["Migraine"],"enrollment":80,"completionDate":"2023-03-09"},{"nctId":"NCT06063369","phase":"PHASE2","title":"PEA vs. Placebo for Major Depression","status":"UNKNOWN","sponsor":"The Israeli Medical Center for Alzheimer's","startDate":"2022-12-21","conditions":["Bipolar Depression","Major Depressive Disorder"],"enrollment":100,"completionDate":"2024-12-21"},{"nctId":"NCT06037993","phase":"NA","title":"Endocannabinoid Activity Remodulation for Psychosis Liability in Youth","status":"UNKNOWN","sponsor":"University of Udine","startDate":"2022-11-01","conditions":["Clinical High Risk for Psychosis","Ultra High Risk for Psychosis","Attenuated Psychotic Symptoms"],"enrollment":20,"completionDate":"2025-11"},{"nctId":"NCT04488926","phase":"PHASE4","title":"Micronized and Ultramicronized Palmitoylethanolamide in Fibromyalgia Patients","status":"COMPLETED","sponsor":"Epitech Group SpA","startDate":"2020-07-16","conditions":["Fibromyalgia"],"enrollment":21,"completionDate":"2022-05-02"},{"nctId":"NCT05984771","phase":"NA","title":"Efficacy and Safety of the Combination of Ten Elements for 6 Months in Patients With Diabetic Neuropathy : A Pilot Study","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2021-01-10","conditions":["Diabetic Neuropathies","Diabetes Mellitus","Dietary Supplement"],"enrollment":70,"completionDate":"2022-06-30"},{"nctId":"NCT05877170","phase":"NA","title":"Impact of Palmitoylethanolamide (PEA) in the Management of Oro-facial Pain","status":"UNKNOWN","sponsor":"University of Catania","startDate":"2020-02-18","conditions":["Oral-facial Pain"],"enrollment":40,"completionDate":"2023-08-17"},{"nctId":"NCT05867693","phase":"NA","title":"Palmitoylethanolamide and Polydatin in Pediatric Irritable Bowel Syndrome","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2023-04-19","conditions":["Irritable Bowel Syndrome"],"enrollment":70,"completionDate":"2024-04-19"},{"nctId":"NCT05317676","phase":"PHASE2","title":"Effect of Palmitoylethanolamide on Reducing Opioid Consumption for Below Knee Fracture Fixation","status":"WITHDRAWN","sponsor":"University of California, Irvine","startDate":"2023-05","conditions":["Tibial Fractures","Fibula Fracture","Knee Fracture"],"enrollment":0,"completionDate":"2025-12"},{"nctId":"NCT05766969","phase":"PHASE1,PHASE2","title":"Diabetic Neuropathic Pain Relief, 6 Weeks Dosage Sublingual Water-soluble CBD/PEA","status":"UNKNOWN","sponsor":"Pure Green Pharmaceuticals Inc.","startDate":"2023-06-05","conditions":["Diabetic Peripheral Neuropathic Pain"],"enrollment":52,"completionDate":"2023-12-05"},{"nctId":"NCT04912921","phase":"NA","title":"Effect of Palmitoylethanolamide on Proinflammatory Markers in Adults Recently Diagnosed With COVID-19","status":"COMPLETED","sponsor":"Arizona State University","startDate":"2020-10-20","conditions":["Inflammation","COVID19"],"enrollment":115,"completionDate":"2022-05-15"},{"nctId":"NCT04619706","phase":"PHASE2","title":"Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19","status":"TERMINATED","sponsor":"Quantum Biopharma","startDate":"2020-12-14","conditions":["COVID-19"],"enrollment":53,"completionDate":"2021-08-24"},{"nctId":"NCT05357157","phase":"","title":"Electroacupuncture Pain Treatment, Mechanical Hyperalgesia, Quality of Life & Expression of Mu+ B Cells in Fibromyalgia","status":"RECRUITING","sponsor":"University of Crete","startDate":"2022-05-31","conditions":["Fibromyalgia","Electroacupuncture","Acupuncture","Hyperalgesia"],"enrollment":80,"completionDate":"2026-12-01"},{"nctId":"NCT05311852","phase":"NA","title":"Effects of PEA-LUT on Frontal Lobe Functions and GABAergic Transmission in Long-Covid Patients","status":"COMPLETED","sponsor":"Department of Neurorehabilitation, Hospital of Vipiteno-Sterzing (BZ) Italy","startDate":"2021-08-16","conditions":["Fatigue","Cognitive Deficit","COVID-19","Neurophysiologic Abnormality"],"enrollment":34,"completionDate":"2022-03-15"},{"nctId":"NCT05242718","phase":"NA","title":"Immune Diversity Response to Oral Dosing of Nutritional Health Products in Healthy Participants","status":"COMPLETED","sponsor":"Immunoflex Therapeutics Inc.","startDate":"2021-01-10","conditions":["Immunity Disorders"],"enrollment":32,"completionDate":"2021-05-20"},{"nctId":"NCT04568876","phase":"PHASE4","title":"Micronized and Ultramicronized Palmitoylethanolamide in COVID-19 Patients","status":"COMPLETED","sponsor":"Epitech Group SpA","startDate":"2020-10-23","conditions":["Covid19"],"enrollment":40,"completionDate":"2021-02-28"},{"nctId":"NCT05017428","phase":"NA","title":"Absorption and Digestion Kinetics of Human Metabolites","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2021-04-08","conditions":["Postprandial Inflammation"],"enrollment":5,"completionDate":"2021-07-01"},{"nctId":"NCT03066193","phase":"PHASE2","title":"Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-02-01","conditions":["Tourette Syndrome"],"enrollment":17,"completionDate":"2018-06-28"},{"nctId":"NCT04091789","phase":"PHASE2","title":"Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea","status":"UNKNOWN","sponsor":"Pure Green","startDate":"2019-09","conditions":["Dysmenorrhea","Headache, Migraine","Fatigue","Nausea","Mood Disturbance"],"enrollment":30,"completionDate":"2020-05"},{"nctId":"NCT04088084","phase":"PHASE2","title":"Effects of Palmitoylethanolamide on Inner Retinal Function in Glaucoma Patients by Pattern Electroretinogram","status":"COMPLETED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2015-03-09","conditions":["Glaucoma"],"enrollment":40,"completionDate":"2017-12-31"},{"nctId":"NCT02699281","phase":"PHASE4","title":"Efficacy of Ultra-micronized Palmitoylethanolamide (Um-PEA) in Geriatric Patients With Chronic Pain","status":"COMPLETED","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2015-10","conditions":["Chronic Pain"],"enrollment":11,"completionDate":"2016-07"},{"nctId":"NCT03651726","phase":"PHASE2","title":"A Study to Examine the Efficacy of a Therapeutic THX-110 for Tourette Syndrome","status":"UNKNOWN","sponsor":"Neurothera Labs Inc.","startDate":"2018-08","conditions":["Tourette Syndrome"],"enrollment":60,"completionDate":"2019-11"},{"nctId":"NCT02372903","phase":"NA","title":"Efficacy of Palmitoylethanolamide-polydatin Combination on Chronic Pelvic Pain in Patients With Endometriosis","status":"COMPLETED","sponsor":"University of Cagliari","startDate":"2013-10","conditions":["Endometriosis","Chronic Pelvic Pain"],"enrollment":30,"completionDate":"2015-09"},{"nctId":"NCT01742247","phase":"PHASE4","title":"Assessment of Needs of Moisturizers After Various Laser Treatments","status":"COMPLETED","sponsor":"Pusan National University Hospital","startDate":"2012-09","conditions":["Dermatologic Disorders","Injury Due to Laser"],"enrollment":20,"completionDate":"2015-12"},{"nctId":"NCT02645461","phase":"NA","title":"Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS","status":"COMPLETED","sponsor":"University of Roma La Sapienza","startDate":"2014-01","conditions":["Amyotrophic Lateral Sclerosis"],"enrollment":50,"completionDate":"2015-12"},{"nctId":"NCT01851499","phase":"NA","title":"Ultramicronized PEA (Normast) in Spinal Cord Injury Neuropathic Pain","status":"COMPLETED","sponsor":"Danish Pain Research Center","startDate":"2013-05","conditions":["Neuropathic Pain","Spinal Cord Injury"],"enrollment":73,"completionDate":"2015-10"},{"nctId":"NCT01370720","phase":"PHASE2","title":"Safety and Efficacy Study of PEA and Polydatin on Intestinal Inflammation and Visceral Hyperalgesia in IBS Patients","status":"UNKNOWN","sponsor":"MARIA CRISTINA COMELLI","startDate":"2010-02","conditions":["Irritable Bowel Syndrome"],"enrollment":60,"completionDate":"2013-01"},{"nctId":"NCT01491191","phase":"NA","title":"Palmitoylethanolamide for Post-operative Pain Prevention","status":"UNKNOWN","sponsor":"University of Modena and Reggio Emilia","startDate":"2012-01","conditions":["Chronic Post-operative Pain"],"enrollment":300,"completionDate":"2013-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"011010","UNII":"6R8T1UDM3V","CHEBI":"CHEBI:71464","INN_ID":"871","RXNORM":"2001986","UMLSCUI":"C0069964","ChEMBL_ID":"CHEMBL417675","KEGG_DRUG":"D08328","DRUGBANK_ID":"DB14043","PUBCHEM_CID":"4671","MESH_SUPPLEMENTAL_RECORD_UI":"C005958"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":9,"therapeuticAreas":["Pain"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Jun","pmid":"41664677","title":"Efficacy, safety, and tolerability of palmitoylethanolamide in the management of diabetic neuropathic pain: a systematic review and meta-analysis.","journal":"Journal of diabetes and metabolic disorders"},{"date":"2023 Mar 10","pmid":"36986081","title":"Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials.","journal":"Nutrients"},{"date":"2019 Jan 8","pmid":"30621775","title":"Clinical applications of palmitoylethanolamide in pain management: protocol for a scoping review.","journal":"Systematic reviews"},{"date":"2017 Jul","pmid":"28727699","title":"Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis.","journal":"Pain physician"},{"date":"2015","pmid":"26604814","title":"Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome.","journal":"Journal of pain research"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Palmitoylethanolamide is a small molecule with the synonyms AM 3112, FSD-201, IMPULSIN, LEVAGEN, LORAMINE P 256, and N(2-HYDROXYETHYL) PALMITIDE. It has been studied in clinical trials for various conditions, including Autism Spectrum Disorder, Inflammation, COVID-19, Dermatologic Disorders, and Injury Due to Laser.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":8,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}